55results about How to "Reduce arrhythmia" patented technology

Method and systems are disclosed for radiating a moving target inside a heart. The method includes acquiring sequential volumetric representations of an area of the heart and defining a target tissue region and / or a radiation sensitive structure region in 3D for a first of the representations. The target tissue region and / or radiation sensitive structure region are identified for another of the representations by an analysis of the area of the heart from the first representation and the other representation. Radiation beams to the target tissue region are fired in response to the identified target tissue region and / or radiation sensitive structure region from the other representation.

A method and system are disclosed for radiosurgical treatment of moving tissues of the heart, including acquiring at least one volume of the tissue and acquiring at least one ultrasound data set, image or volume of the tissue using an ultrasound transducer disposed at a position. A similarity measure is computed between the ultrasound image or volume and the acquired volume or a simulated ultrasound data set, image or volume. A robot is configured in response to the similarity measure and the position of the transducer, and a radiation beam is fired from the configured robot.

Radiosurgical treatment of tissues of the heart to mitigate arrhythmias such as atrial fibrillation or the like. Radiosurgical targeting of the relatively rapid movement of heart tissues may be enhanced by generating a moving model volume using a time-sequence of three dimensional acquired tissue volumes. A digitally reconstructed radiograph (DRR) may be generated from the model at a desired cardiac and / or respiration motion phase and compared to an X-ray or the like taken immediately before or during treatment. When a series of radiation beams will be directed to a heart tissue to alleviate an arrhythmia, the treatment system may alter the radiation beam series in response to the type of the arrhythmia.

Radiosurgical treatments of tissues of the heart mitigate arrhythmias and treat other tumerous and non-tumerous disease using an implanted fiducial positioned in or near the heart using cardiac catheterization techniques. The fiducials may be implanted after diagnostic and planning images of the target tissues have been acquired. Fiducial implantation may take place the day of a scheduled radiosurgical treatment. Techniques to accommodate post-planning fiducial implantation may include registration of the implanted fiducial location with the treatment plan, and active fiducials may limit collateral imaging radiation exposure while enhancing tracking accuracy.

Method and systems are disclosed for radiating a moving target inside a heart. The method includes acquiring sequential volumetric representations of an area of the heart and defining a target tissue region and / or a radiation sensitive structure region in 3D for a first of the representations. The target tissue region and / or radiation sensitive structure region are identified for another of the representations by an analysis of the area of the heart from the first representation and the other representation. Radiation beams to the target tissue region are fired in response to the identified target tissue region and / or radiation sensitive structure region from the other representation.

The present invention is directed to monoclonal antibodies and fragments thereof directed to LRP5 / 6 that find use in the prevention and treatment of cardiac remodeling and cancer. Also disclosed are methods for using such monoclonal antibodies in the prevention and treatment of such diseases.

The invention discloses new application of sodium houttuyfonate in pharmacy, in particular to the application of the sodium houttuyfonate in preparing medicaments for preventing and treating myocardial hypertrophy and / or ventricular hypertrophy. The application is to prepare an in-vitro myocardial cell hypertrophyby adopting three methods of preparing an in-vivo animal model of myocardial hypertrophy and ventricular hypertrophy, culturing a myocardial cell in vitro and inducing epinephrine by isoproterenol, L-thyroxine and abdominal aorta banding. Experiment results prove that the sodium houttuyfonate can reduce the increase of left cardiac index and global cardiac index of a model animal, inhibit hypertrophy of an in-vitro myocardial cell, reduce the cAMP concentration of plasma, the content of Ang II and ET-1 of a myocardial tissue and the content of TNF-alpha and ALD of serum, and can reduce blood pressure and decrease heart rate. Experiment results suggest that the sodium houttuyfonate has the functions of resisting myocardial hypertrophy and ventricular hypertrophy, and the mechanism of the sodium houttuyfonate can be related to the inhibition of sympathetic activity, blockage of system activity of feritin-hypertensin-aldosterone, and effect of endocrine factors.

The invention discloses a traditional Chinese preparation used for treating myocardial infarction caused by myocardial ischemia which comprises the following traditional Chinese materials with the weight account: ginseng of 17 to 22, water frog of 8 to 12, schisandra of 8 to 12, aconite of 8 to 12, salvia of 8 to 12, platyciad semen of 18 to 22, gadfly of 8 to 12, pinellia ternate of 8 to 12, panax notoginseng of 8 to 12, ligusticum wallichii of 8 to 12, musk of 0.8 to 1.2, melon of 13 to 17, Chinese onion of 13 to 17. The invention has the advantages of replenishing qi, activating blood and eliminating phlegm, treating myocardial infarction caused by myocardial ischemia by combining with the western medicine treatment, and reducing the incidence of arrhythmia, pump failure, embolization and other complications obviously; intravenous thromboly treatment significantly lowers the hospitalized death rate.

The present invention provides for methods and compositions for treating and / or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, functional analogue or a pharmaceutically effective salt thereof.

Method and systems are disclosed for radiating a moving target inside a heart. The method includes acquiring sequential volumetric representations of an area of the heart and defining a target tissue region and / or a radiation sensitive structure region in 3D for a first of the representations. The target tissue region and / or radiation sensitive structure region are identified for another of the representations by an analysis of the area of the heart from the first representation and the other representation. Radiation beams to the target tissue region are fired in response to the identified target tissue region and / or radiation sensitive structure region from the other representation.

The invention discloses a natural galenical preparation helping promote dam lactation, which consists of the following raw materials in part by weight: 1 to 6 parts of pawpaw extract, 2 to 4 parts of danshen extract, 1 to 3 parts of white tea extract, 1 to 3 parts of poplar flower extract, 1 to 4 parts of hawthorn extract, 1 to 3 parts of astragalus extract, 1 to 3 parts of pine extract, and 2 to 6 parts of carrier. The preparation method comprises the following steps: respectively extracting pine, pawpaw, danshen, white tea, poplar flower, hawthorn and astragalus; and mixing and stirring the prepared dry powder and the carrier in proportion at normal temperature and under normal pressure to prepare the natural galenical preparation helping promote dam lactation. The natural galenical preparation has the effects of lactation promotion, iron supply, blood and nutrition supply, has no medicament residue, no toxic or side effect, promotes newborn animals to be weaned earlier, improves uniformity degree of the newborn animals, and prolongs the life of rare wild animals.

A catheter for delivery of contrast material for a medical imaging procedure, the catheter comprising: (a) an operative distal head comprising a tubular body including at least two turns and characterized by a transverse proximal aspect that is larger than a transverse distal aspect; and (b) a plurality of contrast material ports distributed along said tubular body between at least two of said at least two turns.

The invention relates to a technology of skin nourishing and protecting, particularly relates to traditional Chinese medicinal anti-senile wrinkle-removing whitening spot-removing acne-removing facial mask powder, and a preparation method and using method thereof, and belongs to the field of medicaments. The facial mask powder is prepared from the following raw materials in parts by weight: 5-25 parts of radix ginseng alba, 5-20 parts of bletilla striata, 5-20 parts of Chinese yam, 5-25 parts of radix paeoniae alba, 5-20 parts of ussuriensis fritillary bulb, 5-25 parts of cortex dictamni, 5-15 parts of apricot, 5-15 parts of ginkgo nut, 5-30 parts of semen coicis, 5-10 parts of pearl powder, 5-20 parts of talc powder, 1-5 parts of peppermint and 5-15 parts of rhizoma kaempferiae. The using method comprises the following steps: weighing 5-8g of facial mask powder; putting the facial mask powder into a container, and mixing with egg white to obtain paste; and applying the paste to a required position on the skin for 40-80 minutes, and cleaning the facial mask powder on the skin with clean water. By using the facial mask powder, the skin and mental states of a user can achieve an excellent state which cannot be achieved by the user self before, and the skin can be bright, moistened and white, and fine wrinkles can be removed.

The invention discloses an application of a morindae officinalis extract and morindae officinalis oligosaccharide pentasaccharide to preparation of a drug for treating myocardial ischemia and / or reperfusion injury and promoting therapeutic angiogenesis. The myocardial ischemia and reperfusion injury belong to secondary injury brought to an organism when the hemoperfusion of myocardium is stopped or poor, i.e., after the myocardium is subjected to ischemia, hypoxia injury, circulation reinstitution and blood supply recovery. The morindae officinalis extract and the morindae officinalis oligosaccharide pentasaccharide both play a role in protecting an in-vivo rat myocardial ischemia reperfusion injury model and an in-vitro purification cultured neonatal rat myocardial cell hypoxia / reoxygenation injury model, and can be used for remarkably reducing the myocardial infarction area and the incidence rate of reperfusion arrhythmias, effectively protecting the form of a myocardial cell and relieving the injury of hypoxia / reoxygenation to the myocardial cell. The therapeutic angiogenesis promotion means that the aims of recovering the blood supply of ischemic myocardium and improving the heart function are achieved through increasing the functional coronary artery branch or side branch under the irritation actions of some methods, including the therapeutic actions of some drugs.

The invention discloses an application of a Morindae officinalis extract product and Morindae officinalis oligosaccharide 6 glycan in the preparation of medicines for resisting myocardial ischemia and / or reperfusion injury and promoting therapeutic angiogenesis. The myocardial ischemia and reperfusion injury are body injuries caused by the afresh circulation establishment and the blood supply recovery during the stopping or abnormality of the myocardial blood perfusion, like ischemic and anoxic injuries. The Morindae officinalis oligosaccharide 6 glycan has a protect effect on an in-vivo rat myocardial ischemia reperfusion injury model and an in-vitro purify-cultured mouse myocardial cell reoxygenation injury model, can substantially reduces the myocardial infarction area, can mitigate the reperfusion arrhythmia, can effectively protect the form of myocardial cells, and can mitigate the injuries of anoxic reoxygenation to the myocardial cells. The therapeutic angiogenesis promotion is characterized in that the ischemic myocardial blood supply recovery and the cardiac function improvement are realized by increasing the functional coronary arterial tree or coronary collateral through some irradiations comprising the treatment effects of some medicines.

The invention discloses a medical polyurethane catheter composed of blended materials of polyurethane comprising 20% of barium sulfate and polyurethane comprising 40% of barium sulfate. The polyurethane materials with different barium sulfate contents are mixed according to different ratios. With the method provided by the invention, prior defects such as catheter hardness and elasticity can both be solved. Bending is prevented during catheterization, and the catheter has the advantages of good elasticity and pressure resistance. When catheter body is softened, the catheter is prevented from being flattened.

The invention discloses white and black nutritional tea. The white and black nutritional tea comprises the following raw materials: lilies, ginkgo, lotus seeds, black rice, black sesames, black beans, the wolfberry fruits, walnut kernels and coix lacryma-jobi kernels. The preparation method for the white and black nutritional tea comprises the following steps: cleaning, pre-drying, ultrafine crushing, low-temperature puffing, cooling, mixing and packaging. With the adoption of an advanced ultrasonic cleaning technology, a microwave drying technology, an ultrafine crushing technology and a low-temperature puffing processing technology, the nutritional values and the health functions of the lilies, the ginkgo, the lotus seeds, the black rice, the black sesames, the black beans, the wolfberry fruits, the walnut kernels and the coix lacryma-jobi kernels can be kept to the maximum extent; the nine traditional Chinese medicines are matched mutually to cooperatively achieve the effects of moistening lung, relieving asthma, strengthening the spleen and stomach, benefiting qi for activating blood circulation, nourishing the liver to improve visual acuity, clearing away heat and toxin, tonifying the brain, soothing the nerve, tranquilizing and aiding sleep, maintaining beauty, keeping young and the like; the white and black nutritional tea also has an anti-cancer effect, is convenient to carry, safe, reliable, obvious in diet therapy effect and suitable for various types of people.

The invention relates to a remote monitoring and early warning system of heart rates in group sports. The remote monitoring and early warning system is characterized by comprising wearable devices, acloud server and a remote heart rate monitoring system; the wearable devices are used for monitoring heart rate data of individuals, the wearable devices send the monitored heart rate data to the cloud server, and the remote heart rate monitoring system is used for collecting the heart rate data of the cloud server in real time, processing the data and carrying out early warning in real time. By means of the remote monitoring and early warning system, the heart rate information monitored by the wearable devices can be sent to the cloud server, terminal devices can collect the data of all the individuals and carry out early warning feedback in real time, it can be achieved that the heart rates in the group sports are integrally collected and early warning is carried out in real time, the problems of arrhythmia even sudden death in the group sports are effectively avoided, and the remote monitoring and early warning system can be widely used for heart rate monitoring of large group sports.

The invention relates to a tablet composition containing enalapril and folic acid and a preparation method thereof. The tablets prepared by the preparation method are capable of effectively reducing the degradation of active ingredients of a medicine while improving the stability and safety of a compound solid preparation as well as the disintegration rate and timeliness of the medicine in the stomach and intestines; the composition meets the dosage requirements for accurate absorption, and the therapeutic effect of the medicine is remarkably improved.

The invention provides an application of hexachlorophene in the preparation of a KCNQ agonist. In addition, the invention provides an application of the hexachlorophene in the preparation of a medicine serving as the KCNQ agonist. In the application, the KCNQ agonist can be a KCNQ1 agonist, a KCNQ1 / KCNE1 agonist, a KCNQ2 agonist or KCNQ2 / KCNQ3 agonist. The hexachlorophene has the effects of shortening the action potential duration and treating the arrhythmia by boosting KCNQ1 / KCNE1 electric currents and promoting the repolarization of the action potential of myocardial cells. The subtype potentiation proves that the hexachlorophene is capable of enhancing KCNQ and M electric currents and has the effects of adjusting the membrane potential level by boosting KCNQ2 electric currents and KCNQ2 / KCNQ3 hetero-oligomer electric currents and weakening the issuing frequency of the action potential; the application of the hexachlorophene in the preparation of medicines taking KCNQ as anti-epileptic targets is realized, and the anti-epileptic effect is achieved.

The 10-23 deoxyribozyme constructed in the invention utilizes in-vitro-transcription ET-1 full-length RNA as s substrate to filter the 10-23 deoxyribozyme with cut ET-1 mRNA, and can reduce the expression of an ET-1 gene of myocardial cells through transfection, inhibit hypertrophy of serum induced myocardial cells, and reduce the damage of hypoxic myocardial cells; the ET-1 10-23 deoxyribozyme can obviously reduce the occurrence of arrhythmia of isolated rat hearts after acute ischemia and improve heart functions. The invention provides tools for further clearing the functions of endogenous ET-1 in acute ischemic arrhythmia, and also provides theoretical basis and new ways of thinking for explaining the mechanism and prevention of and development of new medicaments for the acute ischemic arrhythmia.

The present invention provides for methods and compositions for treating, reducing and / or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, prodrug thereof, functional analog or a pharmaceutically effective salt thereof in an amount sufficient to increase activity of at least one kinase in heart tissue of the subject.

The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.

The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.